Shree Ganesh Remedies Limited (BOM:540737)
India
· Delayed Price · Currency is INR | Market Cap | 7.99B |
| Revenue (ttm) | 1.09B |
| Net Income (ttm) | 230.68M |
| Shares Out | 12.84M |
| EPS (ttm) | 17.96 |
| PE Ratio | 34.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,855 |
| Average Volume | 18,858 |
| Open | 616.70 |
| Previous Close | 610.60 |
| Day's Range | 611.20 - 629.00 |
| 52-Week Range | 600.00 - 950.05 |
| Beta | 0.26 |
| RSI | 40.33 |
| Earnings Date | May 30, 2025 |
About Shree Ganesh Remedies
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India. It provides anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, anti-fungal, anti-histamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary API intermediates. The company also offers fine and specialty chemicals, such as ... [Read more]
Financial Performance
In 2024, Shree Ganesh Remedies's revenue was 1.09 billion, a decrease of -13.74% compared to the previous year's 1.26 billion. Earnings were 230.68 million, a decrease of -17.93%.
Financial StatementsNews
Shree Ganesh Remedies shares tumble over 8% after Q4 net profit drops 48% YoY
Shares of Shree Ganesh Remedies Ltd declined sharply by 8.17% on Tuesday, trading at ₹716 on the BSE, down from the previous close of ₹779.70. The steep fall comes in response to weak Q4 FY25 earnings...
Shree Ganesh Remedies commissions 2.5 MW solar power project, expects Rs 2 crore annual savings
Shree Ganesh Remedies Limited has announced the successful commissioning of a 2.5 MW solar power project, equipped with auto-tracker modules, on March 25, 2025. This project is expected to yield annua...